文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Novel Imaging Methods for Renal Mass Characterization: A Collaborative Review.

作者信息

Roussel Eduard, Capitanio Umberto, Kutikov Alexander, Oosterwijk Egbert, Pedrosa Ivan, Rowe Steven P, Gorin Michael A

机构信息

Department of Urology, University Hospitals Leuven, Leuven, Belgium.

Department of Urology, University Vita-Salute, San Raffaele Scientific Institute, Milan, Italy; Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.

出版信息

Eur Urol. 2022 May;81(5):476-488. doi: 10.1016/j.eururo.2022.01.040. Epub 2022 Feb 22.


DOI:10.1016/j.eururo.2022.01.040
PMID:35216855
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9844544/
Abstract

CONTEXT: The incidental detection of localized renal masses has been rising steadily, but a significant proportion of these tumors are benign or indolent and, in most cases, do not require treatment. At the present time, a majority of patients with an incidentally detected renal tumor undergo treatment for the presumption of cancer, leading to a significant number of unnecessary surgical interventions that can result in complications including loss of renal function. Thus, there exists a clinical need for improved tools to aid in the pretreatment characterization of renal tumors to inform patient management. OBJECTIVE: To systematically review the evidence on noninvasive, imaging-based tools for solid renal mass characterization. EVIDENCE ACQUISITION: The MEDLINE database was systematically searched for relevant studies on novel imaging techniques and interpretative tools for the characterization of solid renal masses, published in the past 10 yr. EVIDENCE SYNTHESIS: Over the past decade, several novel imaging tools have offered promise for the improved characterization of indeterminate renal masses. Technologies of particular note include multiparametric magnetic resonance imaging of the kidney, molecular imaging with targeted radiopharmaceutical agents, and use of radiomics as well as artificial intelligence to enhance the interpretation of imaging studies. Among these, Tc-sestamibi single photon emission computed tomography/computed tomography (CT) for the identification of benign renal oncocytomas and hybrid oncocytic chromophobe tumors, and positron emission tomography/CT imaging with radiolabeled girentuximab for the identification of clear cell renal cell carcinoma, are likely to be closest to implementation in clinical practice. CONCLUSIONS: A number of novel imaging tools stand poised to aid in the noninvasive characterization of indeterminate renal masses. In the future, these tools may aid in patient management by providing a comprehensive virtual biopsy, complete with information on tumor histology, underlying molecular abnormalities, and ultimately disease prognosis. PATIENT SUMMARY: Not all renal tumors require treatment, as a significant proportion are either benign or have limited metastatic potential. Several innovative imaging tools have shown promise for their ability to improve the characterization of renal tumors and provide guidance in terms of patient management.

摘要

相似文献

[1]
Novel Imaging Methods for Renal Mass Characterization: A Collaborative Review.

Eur Urol. 2022-5

[2]
Clinical Performance of Technetium-99m-Sestamibi SPECT/CT Imaging in Differentiating Oncocytic Tumors From Renal Cell Carcinoma in Routine Clinical Practice.

J Urol. 2023-9

[3]
Cost-effectiveness Analysis of Tc-sestamibi SPECT/CT to Guide Management of Small Renal Masses.

Eur Urol Focus. 2021-7

[4]
Prospective Evaluation of (99m)Tc-sestamibi SPECT/CT for the Diagnosis of Renal Oncocytomas and Hybrid Oncocytic/Chromophobe Tumors.

Eur Urol. 2015-9-18

[5]
The Role of Tc-Sestamibi Single-photon Emission Computed Tomography/Computed Tomography in the Diagnostic Pathway for Renal Masses: A Systematic Review and Meta-analysis.

Eur Urol. 2024-1

[6]
Diagnostic Accuracy of Tc-Sestamibi SPECT/CT for Characterization of Solid Renal Masses.

J Nucl Med. 2023-1

[7]
The role of molecular imaging in the characterization of renal masses.

Curr Opin Urol. 2018-3

[8]
Defining the Added Value of 99mTc-MIBI SPECT/CT to Conventional Cross-Sectional Imaging in the Characterization of Enhancing Solid Renal Masses.

Clin Nucl Med. 2017-4

[9]
Characterizing Indeterminate Renal Masses with Molecular Imaging: the Role of Tc-MIBI SPECT/CT.

Curr Urol Rep. 2017-9-12

[10]
Imaging of Chromophobe Renal Cell Carcinoma with Tc-Sestamibi SPECT/CT: Considerations Regarding Risk Stratification and Histologic Reclassification.

Mol Imaging Biol. 2024-10

引用本文的文献

[1]
Utilisation of artificial intelligence to enhance the detection rates of renal cancer on cross-sectional imaging: protocol for a systematic review and meta-analysis.

BMJ Open. 2025-8-31

[2]
18F-FDG PET/CT identifies isolated metastasis of renal cancer in a patient with end-stage renal disease: A case report.

Medicine (Baltimore). 2025-7-25

[3]
Mitophagy related gene signature for prognosis and therapeutic evaluation in KIRC.

Sci Rep. 2025-7-26

[4]
Diagnostic performance of the clear cell likelihood score integrated with cystic degeneration or necrosis on MR imaging for identifying clear cell renal cell carcinoma in cT1 solid renal masses.

Insights Imaging. 2025-7-3

[5]
A comparison of effectiveness of the contrast enhanced computed tomography with magnetic resonance imaging in the differential diagnosis of clear cell renal carcinoma.

Radiol Oncol. 2025-6-16

[6]
A modified Delphi consensus statement on the role of biopsy in small renal masses.

BJUI Compass. 2025-4-22

[7]
Progress in the Application of Artificial Intelligence in Ultrasound-Assisted Medical Diagnosis.

Bioengineering (Basel). 2025-3-13

[8]
Renal Mass Biopsy Prior to Surgical Excision: Practice, Diagnostic Performance, and Impact on Management in the UroCCR Registry (Ancillary Study No. 118).

Eur Urol Open Sci. 2025-2-15

[9]
ZACN Associated with Poor Prognosis Promotes Proliferation of Kidney Renal Clear Cell Carcinoma Cells by Inhibiting JTC801-Induced Alkaliptosis.

Appl Biochem Biotechnol. 2025-5

[10]
CECT-Based Radiomic Nomogram of Different Machine Learning Models for Differentiating Malignant and Benign Solid-Containing Renal Masses.

J Multidiscip Healthc. 2025-1-25

本文引用的文献

[1]
How We Do It: Managing the Indeterminate Renal Mass with the MRI Clear Cell Likelihood Score.

Radiology. 2022-2

[2]
Molecular underpinnings of glandular tropism in metastatic clear cell renal cell carcinoma: therapeutic implications.

Acta Oncol. 2021-11

[3]
Molecular Subtypes and Gene Expression Signatures as Prognostic Features in Fully Resected Clear Cell Renal Cell Carcinoma: A Tailored Approach to Adjuvant Trials.

Clin Genitourin Cancer. 2021-12

[4]
Deciphering Intratumoral Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma with a Radiogenomics Platform.

Clin Cancer Res. 2021-9-1

[5]
PSMA-PET/CT in Patients with Recurrent Clear Cell Renal Cell Carcinoma: Histopathological Correlations of Imaging Findings.

Diagnostics (Basel). 2021-6-23

[6]
Kidney cancer management 3.0: can artificial intelligence make us better?

Curr Opin Urol. 2021-7-1

[7]
MicroRNAs Possibly Involved in the Development of Bone Metastasis in Clear-Cell Renal Cell Carcinoma.

Cancers (Basel). 2021-3-28

[8]
Phase I study to assess safety, biodistribution and radiation dosimetry for Zr-girentuximab in patients with renal cell carcinoma.

Eur J Nucl Med Mol Imaging. 2021-9

[9]
F-PSMA-1007 PET/CT for response assessment in patients with metastatic renal cell carcinoma undergoing tyrosine kinase or checkpoint inhibitor therapy: preliminary results.

Eur J Nucl Med Mol Imaging. 2021-6

[10]
The value of Tc-sestamibi single-photon emission computed tomography-computed tomography in the evaluation and risk stratification of renal masses.

Can Urol Assoc J. 2021-6

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索